Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947012015> ?p ?o ?g. }
- W2947012015 endingPage "701" @default.
- W2947012015 startingPage "691" @default.
- W2947012015 abstract "Introduction: Oral antidiabetic medications are important in many type 2 diabetes care plansAreas covered: The article summarizes the cardiovascular and renal safety data for DPP-4 inhibitors and SGLT-2 inhibitors and specific safety data particular to each class.Expert opinion: DPP-4 and SGLT-2 inhibitors provide unique anti-hyperglycemic mechanisms. The cardiovascular safety profiles of DPP-4 inhibitors are promising, but do not show the strong CV risk reduction of empagliflozin and canagliflozin. The heart failure signal associated with DPP-4 inhibitor use is unclear with differing agents, demonstrating increased risk or maybe even protective effects. The risk reduction in cardiovascular disease associated with SGLT-2 inhibitors has translated to recommendations to consider these therapies early in the treatment pathway. Both classes have potential safety concerns that necessitate appropriate patient selection and thorough education on potential side-effects. DPP-4 inhibitors are considered to have neutral or in some studies beneficial renoprotective effects. SGLT-2 inhibitor safety effects on the kidney are more complex. There are reports of acute kidney injury occurring soon after initiating SGLT-2 inhibitor therapy. However, there are large recent studies that have demonstrated the beneficial effect of SGLT-2 inhibitors in slowing the progression of established chronic kidney disease.Trial registration: ClinicalTrials.gov identifier: NCT01243424.Trial registration: ClinicalTrials.gov identifier: NCT01897532.Trial registration: ClinicalTrials.gov identifier: NCT02065791.Trial registration: ClinicalTrials.gov identifier: NCT01986881." @default.
- W2947012015 created "2019-06-07" @default.
- W2947012015 creator A5030521441 @default.
- W2947012015 creator A5044739438 @default.
- W2947012015 creator A5080379883 @default.
- W2947012015 date "2019-06-07" @default.
- W2947012015 modified "2023-10-16" @default.
- W2947012015 title "An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors" @default.
- W2947012015 cites W1584825319 @default.
- W2947012015 cites W1773086197 @default.
- W2947012015 cites W1834962231 @default.
- W2947012015 cites W1885872317 @default.
- W2947012015 cites W1930603471 @default.
- W2947012015 cites W1935699626 @default.
- W2947012015 cites W1994679938 @default.
- W2947012015 cites W1998401806 @default.
- W2947012015 cites W2002810160 @default.
- W2947012015 cites W2002961599 @default.
- W2947012015 cites W2008346273 @default.
- W2947012015 cites W2008849301 @default.
- W2947012015 cites W2019276898 @default.
- W2947012015 cites W2028317115 @default.
- W2947012015 cites W2030192134 @default.
- W2947012015 cites W2030925240 @default.
- W2947012015 cites W2031730303 @default.
- W2947012015 cites W2034667874 @default.
- W2947012015 cites W2035274147 @default.
- W2947012015 cites W2061457508 @default.
- W2947012015 cites W2063362369 @default.
- W2947012015 cites W2064130493 @default.
- W2947012015 cites W2066566134 @default.
- W2947012015 cites W2067663978 @default.
- W2947012015 cites W2125653714 @default.
- W2947012015 cites W2127854619 @default.
- W2947012015 cites W2129570913 @default.
- W2947012015 cites W2133731486 @default.
- W2947012015 cites W2142830692 @default.
- W2947012015 cites W2144325462 @default.
- W2947012015 cites W2145661125 @default.
- W2947012015 cites W2146264128 @default.
- W2947012015 cites W2146774087 @default.
- W2947012015 cites W2147743786 @default.
- W2947012015 cites W2157551948 @default.
- W2947012015 cites W2158506982 @default.
- W2947012015 cites W2166304122 @default.
- W2947012015 cites W2167706579 @default.
- W2947012015 cites W2171882614 @default.
- W2947012015 cites W2179831365 @default.
- W2947012015 cites W2253976461 @default.
- W2947012015 cites W2290062540 @default.
- W2947012015 cites W2323118609 @default.
- W2947012015 cites W2338042410 @default.
- W2947012015 cites W2341643234 @default.
- W2947012015 cites W2343730112 @default.
- W2947012015 cites W2345908908 @default.
- W2947012015 cites W2417331731 @default.
- W2947012015 cites W2463846283 @default.
- W2947012015 cites W2477411371 @default.
- W2947012015 cites W2500767839 @default.
- W2947012015 cites W2519976593 @default.
- W2947012015 cites W2523736413 @default.
- W2947012015 cites W2530634871 @default.
- W2947012015 cites W2532116684 @default.
- W2947012015 cites W2534221266 @default.
- W2947012015 cites W2566368688 @default.
- W2947012015 cites W2574505741 @default.
- W2947012015 cites W2591687581 @default.
- W2947012015 cites W2619645071 @default.
- W2947012015 cites W2626446274 @default.
- W2947012015 cites W2730056025 @default.
- W2947012015 cites W2740741462 @default.
- W2947012015 cites W2743267681 @default.
- W2947012015 cites W2751630005 @default.
- W2947012015 cites W2763580810 @default.
- W2947012015 cites W2766983721 @default.
- W2947012015 cites W2771424111 @default.
- W2947012015 cites W2772204795 @default.
- W2947012015 cites W2772844083 @default.
- W2947012015 cites W2779077655 @default.
- W2947012015 cites W2783568449 @default.
- W2947012015 cites W2790166173 @default.
- W2947012015 cites W2790193266 @default.
- W2947012015 cites W2792565546 @default.
- W2947012015 cites W2794130465 @default.
- W2947012015 cites W2800654584 @default.
- W2947012015 cites W2805520818 @default.
- W2947012015 cites W2808915250 @default.
- W2947012015 cites W2810458929 @default.
- W2947012015 cites W2887766728 @default.
- W2947012015 cites W2890465901 @default.
- W2947012015 cites W2895533920 @default.
- W2947012015 cites W2898385901 @default.
- W2947012015 cites W2900102850 @default.
- W2947012015 cites W2900413769 @default.
- W2947012015 cites W2907458346 @default.
- W2947012015 cites W2910356138 @default.
- W2947012015 cites W2939222610 @default.
- W2947012015 cites W4211190017 @default.